AR033639A1 - Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis - Google Patents

Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis

Info

Publication number
AR033639A1
AR033639A1 ARP990104133A ARP990104133A AR033639A1 AR 033639 A1 AR033639 A1 AR 033639A1 AR P990104133 A ARP990104133 A AR P990104133A AR P990104133 A ARP990104133 A AR P990104133A AR 033639 A1 AR033639 A1 AR 033639A1
Authority
AR
Argentina
Prior art keywords
risk
vertebral
suffering
osteoporosis
reduce
Prior art date
Application number
ARP990104133A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033639(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR033639A1 publication Critical patent/AR033639A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Uso de una hormona paratiroidea caracterizado porque comprende la preparación de medicamentos para reducir el riesgo de fracturas óseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis, sin administración concurrente de agentes de resorción ósea diferentes de la vitamina D o calcio, dichos medicamentos formulados en dosis para la administración diaria de 20 a 40 microg de dicha hormona.
ARP990104133A 1998-08-19 1999-08-18 Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis AR033639A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
AR033639A1 true AR033639A1 (es) 2004-01-07

Family

ID=26792729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104133A AR033639A1 (es) 1998-08-19 1999-08-18 Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis

Country Status (33)

Country Link
US (2) US6977077B1 (es)
EP (3) EP2907522B1 (es)
JP (5) JP2002523375A (es)
KR (1) KR100454207B1 (es)
CN (1) CN1205997C (es)
AR (1) AR033639A1 (es)
AT (1) ATE231000T1 (es)
AU (1) AU746277B2 (es)
BR (1) BR9909445A (es)
CA (1) CA2325371C (es)
CO (1) CO5130020A1 (es)
CY (2) CY1113343T1 (es)
CZ (1) CZ301017B6 (es)
DE (2) DE69904918T2 (es)
DK (4) DK1059933T3 (es)
DZ (1) DZ2873A1 (es)
EA (1) EA003362B1 (es)
ES (4) ES2621653T3 (es)
HK (3) HK1030545A1 (es)
HR (1) HRP20000755A2 (es)
HU (2) HU1200430D0 (es)
ID (1) ID29039A (es)
IL (2) IL138829A0 (es)
MY (1) MY129227A (es)
NO (2) NO323984B1 (es)
NZ (1) NZ507056A (es)
PE (1) PE20001089A1 (es)
PL (1) PL201688B1 (es)
PT (4) PT2266598T (es)
TR (1) TR200003455T2 (es)
TW (1) TW576747B (es)
UA (1) UA72205C2 (es)
WO (1) WO2000010596A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
CA2472472A1 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
EP1667689A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
CA2566032A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1879608A4 (en) * 2005-05-11 2009-11-11 Unigene Lab Inc METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
CA2710798A1 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
KR20190095552A (ko) * 2009-09-09 2019-08-14 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
EP2686027B1 (en) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmaceutical formulation for use in spinal fusion
US20140088014A1 (en) 2011-06-07 2014-03-27 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity pth and method for producing same
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2017214277B2 (en) * 2016-02-01 2020-02-27 Eli Lilly And Company Parathyroid hormone – anti-RANKL antibody fusion compounds
EP3576774A4 (en) * 2017-02-01 2020-10-07 The Johns Hopkins University PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
HU218940B (hu) * 1994-12-22 2001-01-29 Astra Aktiebolag Paratiroid hormont (PHT) tartalmazó, inhalációs célra szolgáló gyógyszerkészítmény, eljárás előállítására, alkalmazása inhalációs készülék töltésére és ezt tartalmazó inhalációs készülék
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
EP1005359B1 (en) * 1997-09-09 2005-06-15 F. Hoffmann-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
CO5130020A1 (es) 2002-02-27
DK2907522T1 (da) 2015-10-19
EP2266598A1 (en) 2010-12-29
DK1059933T3 (da) 2003-04-07
JP6177718B2 (ja) 2017-08-09
AU5575099A (en) 2000-03-14
PL201688B1 (pl) 2009-04-30
ES2190244T3 (es) 2003-07-16
DK2907522T3 (en) 2017-10-23
NZ507056A (en) 2003-10-31
HK1102496A1 (en) 2007-11-23
HUP0101594A3 (en) 2002-01-28
ES2549551T1 (es) 2015-10-29
PT2907522T (pt) 2017-10-23
CA2325371A1 (en) 2000-03-02
US7163684B2 (en) 2007-01-16
US20050197294A1 (en) 2005-09-08
DK1769804T3 (da) 2012-10-15
DE15152726T1 (de) 2015-12-10
HU230697B1 (hu) 2017-09-28
EP2907522A1 (en) 2015-08-19
EP1059933B1 (en) 2003-01-15
PT2266598T (pt) 2017-05-02
CN1308545A (zh) 2001-08-15
TW576747B (en) 2004-02-21
EA003362B1 (ru) 2003-04-24
KR20010072763A (ko) 2001-07-31
CA2325371C (en) 2004-08-17
EP1059933A1 (en) 2000-12-20
JP2015028065A (ja) 2015-02-12
ID29039A (id) 2001-07-26
IL138829A (en) 2011-01-31
DE69904918D1 (de) 2003-02-20
KR100454207B1 (ko) 2004-10-26
HRP20000755A2 (en) 2001-02-28
PL343595A1 (en) 2001-08-27
ES2621653T3 (es) 2017-07-04
PT1769804E (pt) 2012-11-13
ES2549551T3 (es) 2017-11-27
BR9909445A (pt) 2000-12-12
JP2014139220A (ja) 2014-07-31
CZ20004134A3 (cs) 2001-08-15
PT1059933E (pt) 2003-06-30
EP2907522B1 (en) 2017-08-02
NO20005947D0 (no) 2000-11-24
JP2011021035A (ja) 2011-02-03
HK1030545A1 (en) 2001-05-11
NO323984B1 (no) 2007-07-30
UA72205C2 (uk) 2005-02-15
JP2017190332A (ja) 2017-10-19
HK1212602A1 (zh) 2016-06-17
DZ2873A1 (fr) 2003-12-15
ES2393200T3 (es) 2012-12-19
ATE231000T1 (de) 2003-02-15
HUP0101594A2 (hu) 2001-11-28
TR200003455T2 (tr) 2001-06-21
AU746277B2 (en) 2002-04-18
JP2002523375A (ja) 2002-07-30
CN1205997C (zh) 2005-06-15
US6977077B1 (en) 2005-12-20
PE20001089A1 (es) 2000-11-04
CY1119552T1 (el) 2018-03-07
HU1200430D0 (hu) 2001-11-28
DE69904918T2 (de) 2003-11-13
NO20005947L (no) 2000-11-24
IL138829A0 (en) 2001-10-31
CZ301017B6 (cs) 2009-10-14
CY1113343T1 (el) 2016-06-22
DK2266598T3 (en) 2017-05-15
EA200001015A1 (ru) 2001-02-26
WO2000010596A1 (en) 2000-03-02
EP2266598B1 (en) 2017-02-22
NO20072983L (no) 2000-11-24
MY129227A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
AR033639A1 (es) Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
ES2167899T3 (es) Extractos de plantas para el tratamiento de resorcion osea incrementada.
JP2002523375A5 (es)
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
AR029159A1 (es) Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonal
BR0316906A (pt) administração do capsaicinoides
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
EP1417975A4 (en) AGENT FOR THE TREATMENT OF DISEASES COMING WITH BONE SCONES WITH EP SB 4 / SB AGONIST AS AN ACTIVE AGENT
DK1001802T3 (da) Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
DE122006000057I1 (de) Proteinhaltige Arzneimittel
ATE356631T1 (de) Orale verabreichung von parathyroidhormon und calcitonin
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
NO20040598L (no) 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter.
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
BR9808233A (pt) Preparação farmacêutica
CA2385755A1 (en) Prevention of colorectal cancer
ES2151486T3 (es) Composiciones farmaceuticas que contienen complejos de 3-hidroxi-4-pironas.
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน
ITRM20000688A0 (it) Uso della isovaleril l-carnitina per la preparazione di un medicamento per la prevenzione e cura dell'osteoporosi.
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms
HRP20020666B1 (en) Drospirenone for hormone replacement therapy
CO4920257A1 (es) Metodo para disminuir el riesgo de fracturas vertebrales y no vertebrales

Legal Events

Date Code Title Description
FB Suspension of granting procedure